Biomea Fusion (BMEA) Stock Forecast & Price Target

$5.95 +0.31 (+5.50%)

(As of 01:18 PM ET)

Biomea Fusion - Analysts' Recommendations and Stock Price Forecast (2025)

MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0 to .5 = Strong Sell, .5 to 1 = Sell, 1 to 1.5 = Reduce, 1.5 to 2.5 = Hold, 2.5 to 3.0 = Moderate Buy, 3.0 to 3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.

Consensus Rating

Buy

Based on 13 Analyst Ratings

Sell
0

Hold
2

Buy
11

Based on 13 Wall Street analysts who have issued ratings for Biomea Fusion in the last 12 months, the stock has a consensus rating of "Buy." Out of the 13 analysts, 2 have given a hold rating, 9 have given a buy rating, and 2 have given a strong buy rating for BMEA.

Consensus Price Target

$39.36
561.57% Upside

According to the 13 analysts' twelve-month price targets for Biomea Fusion, the average price target is $39.36. The highest price target for BMEA is $128.00, while the lowest price target for BMEA is $11.00. The average price target represents a forecasted upside of 561.57% from the current price of $5.95.

Get the Latest News and Ratings for BMEA and Related Stocks

Enter your email address to receive the latest news and analysts' ratings for Biomea Fusion and its competitors.

BMEA Analyst Ratings Over Time

Type	Current Forecast 12/17/23 to 12/16/24	1 Month Ago 11/17/23 to 11/16/24	3 Months Ago 9/18/23 to 9/17/24	1 Year Ago 12/17/22 to 12/17/23
Strong Buy	2 Strong Buy rating(s)	2 Strong Buy rating(s)	0 Strong Buy rating(s)	0 Strong Buy rating(s)
Buy	9 Buy rating(s)	8 Buy rating(s)	6 Buy rating(s)	8 Buy rating(s)
Hold	2 Hold rating(s)	2 Hold rating(s)	3 Hold rating(s)	1 Hold rating(s)
Sell	0 Sell rating(s)	0 Sell rating(s)	0 Sell rating(s)	0 Sell rating(s)
Consensus Price Target	$39.36	$30.50	$25.33	$48.50
Forecasted Upside	561.57% Upside	367.08% Upside	206.70% Upside	242.27% Upside
Consensus Rating	Buy	Buy	Moderate Buy	Moderate Buy

URGENT: This Altcoin Opportunity Won’t Wait – Act Now (Ad)

It’s here. This is the moment we’ve been waiting for. The next 3-6 months in crypto will be absolutely life-changing for those who are prepared. Why? Because altcoin prices are about to explode.

>> Register for the Workshop Now

BMEA Analyst Recommendations By Month

The chart below shows how a company's ratings by analysts have changed over time. Each bar represents the previous year of ratings for that month. Within each bar, the sell ratings are shown in red, the hold ratings are shown in yellow, the buy ratings are shown in green, and the strong buy ratings are shown in dark green.

BMEA Price Targets by Month

The chart below shows how a company's share price and consensus price target have changed over time. The dark blue line represents the company's actual price. The lighter blue line represents the stock's consensus price target. The even lighter blue range in the background of the two lines represents the low price target and the high price target for each stock.

Biomea Fusion Stock vs. The Competition

Type	Biomea Fusion	Medical Companies	S&P 500
Consensus Rating Score	3.00	2.81	2.51
Consensus Rating	Buy	Moderate Buy	Moderate Buy
Predicted Upside	597.94% Upside	29,826.32% Upside	10.64% Upside
News Sentiment Rating	Neutral News See Recent BMEA News	Positive News	Positive News

Recent Analyst Forecasts and Stock Ratings

Rating

Upside/Downside

Action

Time Frame

Start Date

End Date

Show

Export to Excel

Date	Brokerage	Analyst Name	Action	Rating	Price Target	Upside/Downside on Report Date
12/16/2024	HC Wainwright 2 of 5 stars		Reiterated Rating	Buy ➝ Buy	$40.00 ➝ $40.00	+609.22%
12/10/2024	D. Boral Capital 0 of 5 stars		Reiterated Rating	Buy ➝ Buy	$128.00 ➝ $128.00	+2,110.70%
10/31/2024	Piper Sandler 2 of 5 stars		Boost Target	Overweight ➝ Overweight	$10.00 ➝ $19.00	+96.28%
10/30/2024	Barclays Subscribe to MarketBeat All Access for the recommendation accuracy rating		Boost Target	Equal Weight ➝ Equal Weight	$9.00 ➝ $11.00	-4.84%
10/9/2024	EF Hutton Acquisition Co. I Subscribe to MarketBeat All Access for the recommendation accuracy rating	J. Kolbert Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Strong-Buy
9/27/2024	Scotiabank Subscribe to MarketBeat All Access for the recommendation accuracy rating		Boost Target	Sector Outperform ➝ Sector Outperform	$21.00 ➝ $41.00	+307.15%
URGENT: This Altcoin Opportunity Won’t Wait – Act Now (Ad) It’s here. This is the moment we’ve been waiting for. The next 3-6 months in crypto will be absolutely life-changing for those who are prepared. Why? Because altcoin prices are about to explode. >> Register for the Workshop Now
9/27/2024	Truist Financial Subscribe to MarketBeat All Access for the recommendation accuracy rating	S. Devarakonda Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Hold ➝ Buy	$54.00 ➝ $54.00	+464.26%
9/26/2024	RODMAN&RENSHAW Subscribe to MarketBeat All Access for the recommendation accuracy rating	T. Butler Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Strong-Buy
9/26/2024	Rodman & Renshaw Subscribe to MarketBeat All Access for the recommendation accuracy rating		Upgrade	Neutral ➝ Buy	$18.00	+94.38%
8/29/2024	Capital One Financial Subscribe to MarketBeat All Access for the recommendation accuracy rating	N. Quibria Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Overweight	$25.00	+231.56%
8/27/2024	Citigroup Subscribe to MarketBeat All Access for the recommendation accuracy rating		Lower Target	Buy ➝ Buy	$45.00 ➝ $22.00	+182.05%
5/30/2024	Oppenheimer Subscribe to MarketBeat All Access for the recommendation accuracy rating		Lower Target	Outperform ➝ Outperform	$70.00 ➝ $60.00	+442.01%
5/3/2024	JPMorgan Chase & Co. Subscribe to MarketBeat All Access for the recommendation accuracy rating		Boost Target	Neutral ➝ Neutral	$14.00 ➝ $15.00	+21.95%
6/26/2023	Jefferies Financial Group Subscribe to MarketBeat All Access for the recommendation accuracy rating		Downgrade	Buy ➝ Hold
3/24/2023	Keefe, Bruyette & Woods Subscribe to MarketBeat All Access for the recommendation accuracy rating		Reiterated Rating	Buy	$22.00	+39.24%

Analyst ratings data on MarketBeat is provided by Benzinga and other data providers. This page was last refreshed on Monday at 01:37 PM ET.

BMEA Forecast - Frequently Asked Questions

: According to the research reports of 13 Wall Street equities research analysts, the average twelve-month stock price forecast for Biomea Fusion is $39.36, with a high forecast of $128.00 and a low forecast of $11.00.
: 13 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Biomea Fusion in the last twelve months. There are currently 2 hold ratings, 9 buy ratings and 2 strong buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" BMEA shares.
: According to analysts, Biomea Fusion's stock has a predicted upside of 561.57% based on their 12-month stock forecasts.
: Over the previous 90 days, Biomea Fusion's stock had 4 upgrades by analysts.
: Biomea Fusion has been rated by research analysts at Barclays, D. Boral Capital, EF Hutton Acquisition Co. I, HC Wainwright, Piper Sandler, Rodman & Renshaw, RODMAN&RENSHAW, Scotiabank, and Truist Financial in the past 90 days.
: Analysts like Biomea Fusion more than other "medical" companies. The consensus rating for Biomea Fusion is Buy while the average consensus rating for "medical" companies is Moderate Buy. Learn more on how BMEA compares to other companies.

Stock Forecasts and Research Tools

Related Companies

Today's Ratings

Top Rated Stocks

More Ratings Tools

URGENT: This Altcoin Opportunity Won’t Wait – Act Now (Ad)

It’s here. This is the moment we’ve been waiting for. The next 3-6 months in crypto will be absolutely life-changing for those who are prepared. Why? Because altcoin prices are about to explode.

>> Register for the Workshop Now

This page (NASDAQ:BMEA) was last updated on 12/16/2024 by MarketBeat.com Staff

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Biomea Fusion (BMEA) Stock Forecast & Price Target